Werewolf Therapeutics, Inc.

Equities

HOWL

US95075A1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
5.87 ^USD	+0.51%		+15.78%	+52.07%

Apr. 05	Werewolf Therapeutics, Inc. Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics	CI
Apr. 03	JMP Securities Starts Werewolf Therapeutics With Market Outperform Rating, $12 Price Target	MT

Werewolf Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 10, 2022 at 07:05 am EDT

Werewolf Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 15.34 million compared to USD 7.44 million a year ago. Basic loss per share from continuing operations was USD 0.56 compared to USD 83.36 a year ago.

Latest news about Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc. Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics	Apr. 05	CI
JMP Securities Starts Werewolf Therapeutics With Market Outperform Rating, $12 Price Target	Apr. 03	MT
Werewolf Therapeutics' Q4 Net Loss Narrows	Mar. 07	MT
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Werewolf Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Werewolf Therapeutics, Inc. Appoints Michael Atkins to its Board of Directors	Jan. 04	CI
North American Morning Briefing : Stocks Seen -2-	Nov. 15	DJ
Werewolf Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	Nov. 03	MT
Sector Update: Health Care	Nov. 03	MT
Top Midday Gainers	Nov. 03	MT
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer?s 38th Annual Meeting	Nov. 03	CI
Werewolf Therapeutics, Inc. to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's 38th Annual Meeting	23-10-31	CI
Top Premarket Decliners	23-09-25	MT
Wedbush Starts Werewolf Therapeutics at Outperform With $9 Price Target	23-08-24	MT
Werewolf Therapeutics, Inc. Announces the Investigational New Drug Application Clearance of JZP898 (Formerly Wtx-613), an Engineered IFN Indukine Molecule	23-08-10	CI
Werewolf Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Werewolf Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
Werewolf Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
Werewolf Therapeutics, Inc. Anticipates Multiple Catalysts as the Company Progress the Company's Two Clinical Stage Programs, WTX-124 and WTX-330	23-03-23	CI
North American Morning Briefing : Traders Reassess -2-	23-03-23	DJ
Werewolf Therapeutics Doses First Patient in Phase 1 Study of Potential Solid Tumor Drug	23-02-24	MT
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330	23-02-24	CI
Werewolf Therapeutics, Inc.(NasdaqGS:HOWL) dropped from NASDAQ Biotechnology Index	22-12-16	CI

Chart Werewolf Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the bodyâs immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - American Association of Immunologists Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Werewolf Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.87 USD

Average target price

12.5 USD

Spread / Average Target

+112.95%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
WEREWOLF THERAPEUTICS, INC.	+52.07%	254M
IQVIA HOLDINGS INC.	-1.82%	41.35B
LONZA GROUP AG	+42.44%	40.38B
MODERNA, INC.	+2.56%	39.05B
CELLTRION, INC.	-12.11%	26.67B
ICON PUBLIC LIMITED COMPANY	+3.09%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.16%	18.36B
MEDPACE HOLDINGS, INC.	+22.12%	11.6B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.74%	11.68B
UNITED THERAPEUTICS CORPORATION	+7.75%	11.15B

Other Biotechnology & Medical Research